N-(Pyrimidin-4-yl) and N-(Pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists
John Porter(UCB Pharma (United Kingdom)), Ted A.H. Parton(UCB Pharma (United Kingdom)), Graham J. Warrellow, Sarah C. Archibald(UCB Pharma (United Kingdom)), Anthony Shock(Universitat Autònoma de Barcelona), Brian Hutchinson(Joint Global Change Research Institute), Julien A. Brown, John C. Head, David R. Critchley(University of Leicester), Kirstie Childs(UCB Pharma (United Kingdom)), Martyn K. Robinson(Wellcome Centre for Cell-Matrix Research)
Cited by 8
Related Papers
Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions
|The American Journal of Surgical Pathology|2003|611
Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines
|Nature Immunology|2005|405
PRCC-TFE3 Renal Carcinomas
|The American Journal of Surgical Pathology|2002|362
Renal Carcinomas With the t(6;11)(p21;q12)
|The American Journal of Surgical Pathology|2005|291
Translocation Carcinomas of the Kidney After Chemotherapy in Childhood
|Journal of Clinical Oncology|2006|275